<DOC>
	<DOCNO>NCT00327496</DOCNO>
	<brief_summary>Hepatoma rank first cancer mortality list Taiwan , currently effective treatment option advance HCC . Therefore , alternative medical intervention need improve survival quality life patient . Dendritic cell potent type antigen present cell human body , involve regulation innate adoptive immune response . If use mature antigen present cell pulse vitro appropriate tumor associate antigen optimal activation condition . It anticipate treatment might generate reactivate cytotoxic T lymphocyte response tumor cell thereby inhibit tumor growth . Although excited result tumor vaccine animal model successful clinical try rare . There still problem need resolve immune deficiency cancer patient defect T cell receptor problem tumor escape . There complex composition tumor cell tumor antigen influence efficacy tumor vaccine , go use tumor lysate tumor antigen . In study , generation dendritic cell patient â€™ peripheral blood use rhGM-CSF rhIL-4 stimulating factor , mature dendritic cell pulse tumor lysate , ex vivo T cell cytotoxicity primary tumor cell test . We hope cooperate basic study group hospital ex vivo test clinical trial future .</brief_summary>
	<brief_title>Cytotoxicity Induced Tumor Lysate Pulsed Dendritic Cells Against Autologous Hepatocellular Carcinoma Cells</brief_title>
	<detailed_description>Hepatoma rank first two cancer mortality list Taiwan , currently effective treatment option advance HCC . Therefore , novel medical intervention need improve survival quality life patient . Dendritic cell potent type antigen present cell human body , involve regulation innate adoptive immune response . It assume matured antigen present cell pulse vitro appropriate tumor associate antigen optimal activation condition might generate activate cytotoxic T lymphocyte response tumor cell thereby inhibit tumor growth ( 1,2 ) . Although exciting result tumor vaccine animal model successful clinical try lack . There problem need resolve immune deficiency cancer patient , defect T cell receptor immune evasion tumor . The efficacy tumor vaccine mainly affect heterogenicity tumor cell complexity tumor antigen . Tumor lysates include multiple antigen , suppose good source tumor antigen ( 3-7 ) . The purpose study investigate ability autologous peripheral blood monocyte-derived dendritic cell ( DCs ) hepatoma patient pulse autologous tumor lysate elicit T cell cytotoxicity hepatoma cell ex vivo . We plan HCC primary culture DCs derive peripheral blood monocyte trigger differentiation recombinant human granulocyte macrophage colony stimulate factor ( rhGM-CSF ) interleukin-4 ( rhIL-4 ) immature DCs . Immature DCs pulse autologous hepatoma cell lysates mature use cytokine cocktail . Surface molecule expression DCs analyse flow cytometry . The ability pulse DCs stimulate autologous T cell proliferation assess use carboxyfluorescein diacetate , succinimidyl ester ( CFSE ) staining . The cytotoxicity DC-stimulated T cell primarily culture hepatoma cell estimate use trypan blue exclusion test . The purpose investigate ability autologous peripheral blood monocyte-derived dendritic cell ( DCs ) hepatoma patient pulse autologous tumor lysate elicit T cell cytotoxicity hepatoma cell ex vivo . Reference 1 . Liu KJ , Wang CC , Chen LT , Cheng AL , Lin DT , Wu YC , Yu WL , Hung YM , Yang HY , Juang SH , Whang-Peng J . Generation carcinoembryonic antigen ( CEA ) -specific T-cell response HLA-A*0201 HLA-A*2402 late-stage colorectal cancer patient vaccination dendritic cell load CEA peptide . Clin Cancer Res . 2004 Apr 15 ; 10 ( 8 ) :2645-51 . PMID : 15102666 2 . Chan RC , Pang XW , Wang YD , Chen WF , Xie Y. Transduction dendritic cell recombinant adenovirus encode HCA661 activate autologous cytotoxic T lymphocytes target hepatoma cell . Br J Cancer . 2004 Apr 19 ; 90 ( 8 ) :1636-43 . PMID : 15083197 3 . Iwashita Y , Tahara K , Goto S , Sasaki A , Kai S , Seike M , Chen CL , Kawano K , Kitano S. A phase I study autologous dendritic cell-based immunotherapy patient unresectable primary liver cancer . Cancer Immunol Immunother . 2003 Mar ; 52 ( 3 ) :155-61 . Epub 2003 Feb 06 . PMID : 12649744 4 . Ladhams A , Schmidt C , Sing G , Butterworth L , Fielding G , Tesar P , Strong R , Leggett B , Powell L , Maddern G , Ellem K , Cooksley G. Treatment non-resectable hepatocellular carcinoma autologous tumor-pulsed dendritic cell . J Gastroenterol Hepatol . 2002 Aug ; 17 ( 8 ) :889-96 . PMID : 12164965 5 . Parajuli P , Sloan AE . Dendritic cell-based immunotherapy malignant glioma . Cancer Invest . 2004 ; 22 ( 3 ) :405-16 . PMID : 15493362 6 . Song SY , Kim HS . Strategies improve dendritic cell-based immunotherapy cancer . Yonsei Med J . 2004 Jun 30 ; 45 Suppl:48-52 . PMID : 15250050 7 . Figdor CG , de Vries IJ , Lesterhuis WJ , Melief CJ . Dendritic cell immunotherapy : mapping way . Nat Med . 2004 May ; 10 ( 5 ) :475-80 . PMID : 15122249</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Hepatoma patient indicate operation With major systemic disease include cancer coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2005</verification_date>
</DOC>